(Q43902936)

27 November 2017

title

HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer (English)

1 reference

27 November 2017

11

1 reference

27 November 2017

C Perisanidis

1

1 reference

27 November 2017

B Savarese-Brenner

2

1 reference

27 November 2017

T Würger

3

1 reference

27 November 2017

F Wrba

4

1 reference

27 November 2017

A Huynh

5

1 reference

27 November 2017

C Schopper

6

1 reference

27 November 2017

G Kornek

7

1 reference

27 November 2017

E Selzer

8

1 reference

27 November 2017

R Ewers

9

1 reference

27 November 2017

A Psyrri

10

1 reference

27 November 2017

M Filipits

12

1 reference

27 November 2017

publication date

14 August 2012

1 reference

27 November 2017

1 reference

27 November 2017

volume

19

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

206-211

1 reference

The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Insulin-like growth factor receptor as a therapeutic target in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Non-smoking and non-drinking patients with head and neck squamous cell carcinoma: a distinct population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Epidermal growth factor receptor biology in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Receptor downregulation and multivesicular-body sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Molecular Architecture and Functional Model of the Complete Yeast ESCRT-I Heterotetramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Oral squamous cell carcinoma overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-0825.2012.01972.X

10.1111/J.1601-0825.2012.01972.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference